Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eledon Pharmaceuticals, Inc.

3.62
-0.1100-2.95%
Post-market: 3.690.0700+1.93%18:24 EDT
Volume:538.65K
Turnover:2.00M
Market Cap:216.77M
PE:-11.47
High:3.85
Open:3.85
Low:3.60
Close:3.73
Loading ...
May 31, 2022

Major Issues Report

8-K - Current report
May 12, 2022

Major Issues Report

8-K - Current report
May 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 24, 2022

Major Issues Report

8-K - Current report
Mar 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 28, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 26, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 13, 2022

Major Issues Report

8-K - Current report
Jan 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Aug 19, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Jul 09, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Jul 02, 2021

Major Issues Report

8-K - Current report
Jun 16, 2021

Major Issues Report

8-K - Current report
May 18, 2021

Correspondence

CORRESP [Cover] - Correspondence
May 14, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2021

Major Issues Report

8-K - Current report